Prime Therapeutics’ leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years
Prime Therapeutics
August 25, 2025
Findings also show improved persistence with high-potency, obesity-approved GLP-1 products Eagan, Minn. – June 25, 2025 – Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1)
